Clinical trials: Double-blind Randomized Controlled Study
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
- Trial name
- NCT04847557
- Testing
- Tirzepatide
- Where
- 146 sites in United States, Argentina and 8 more
- Volunteers
- 731 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Atopic
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of bermekimab in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- GENESIS (NCT04791319)
- Testing
- Bermekimab, Dupilumab
- Where
- 42 sites in United States, Canada and 3 more
- Volunteers
- 199 people
- Sponsor
- Janssen Research & Development, LLC
Lupus
Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)
The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.3-30 mg/kg, in adult patients with SLE and who are…
- Trial name
- NCT00299819
- Testing
- MEDI-545, MEDI 545
- Where
- 21 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- MedImmune LLC
Schizophrenia
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
This multi-center, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in participants with persistent, predominant negative symptoms of schizophrenia.
- Trial name
- NCT01192867
- Testing
- RO4917838, Antipshychotics (Standard of Care)
- Where
- 122 sites in United States, Argentina and 12 more
- Volunteers
- 629 people
- Sponsor
- Hoffmann-La Roche
Chronic Spontaneous Urticaria
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.
This is a randomized, double-blind, placebo-controlled phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HS-10561 capsule in healthy Chinese adults and patients with…
- Trial name
- NCT06864507
- Testing
- HS-10561
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Healthy Subjects
Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects
The study will assess the corrected QT (QTc) effects (electrocardiogram [ECG]) of motixafortide (BL-8040) 1.25 mg/kg (therapeutic dose) and 2 mg/kg (supratherapeutic dose) following a single subcutaneous (SC) injection relative…
- Trial name
- NCT05293171
- Testing
- 2 mg/kg BL-8040, 400 mg Moxifloxacin (1x400 mg tablet)
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- BioLineRx, Ltd.
Healthy
Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers
This study is a phase 1 study of PF-06700841. PF-06700841 is being developed for treatment of inflammatory bowel disease. The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of…
- Trial name
- NCT03236493
- Testing
- PF-06700841
- Where
- Belgium
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
Colorectal Cancer Metastatic, Colorectal Cancer Recurrent
Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3, whose anti-tumor and anti-angiogenesis effects have been validated in preclinical tests.
- Trial name
- FACT (NCT02390947)
- Testing
- Famitinib
- Where
- 44 sites in China
- Volunteers
- 543 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Restless Legs Syndrome
XP13512 vs. Placebo in Patients With Restless Legs Syndrome.
The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).
- Trial name
- NCT00365352
- Testing
- XP13512 600MG, XP13512 1200MG
- Volunteers
- 325 people
- Sponsor
- XenoPort, Inc.
Cognitive Change
CMI-168 on Cognitive Function in Healthy Middle-aged Men and Women
The investigators propose to conduct the present study in order to primarily assess the effects of CMI-168 in neurocognition enhancement.
- Trial name
- NCT03612752
- Testing
- CMI-168
- Where
- Taiwan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Cerebos Pacific Limited
Vasculogenic Erectile Dysfunction
Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT) by 'Renova' for Patients With Erectile Dysfunction
This is a prospective, randomized, double-blind clinical study for assessing the safety and efficacy of the treatments performed with Renova (LI-ESWT) on symptomatic ED patients.
- Trial name
- NCT01814852
- Testing
- Shockwave system
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Initia
Covid19
Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants
This is a multi-site, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of ZnAg liquid solution in symptomatic participants with acute COVID-19 that are not hospitalized at the time of…
- Trial name
- NCT04610138
- Testing
- CNM-ZnAg
- Where
- 5 sites in Brazil
- Volunteers
- 296 people
- Sponsor
- Clene Nanomedicine
Type 1 Diabetes
A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes
Primary Objective: To compare exposure and activity of SAR342434 to US-approved and EU-approved Humalog®. Secondary Objective: To assess the safety and tolerability of SAR342434.
- Trial name
- NCT02273258
- Testing
- SAR342434, Insulin Lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Sanofi
Muscular Dystrophies
A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects
The purpose of this study is investigate the pharmacokinetics, safety and tolerability of single subcutaneous administration of GSK2402968 in non-ambulant boys with Duchenne muscular dystrophy
- Trial name
- DEMAND I (NCT01128855)
- Testing
- 3 mg/kg GSK2402968, 6 mg/kg GSK2402968, 9 mg/kg GSK2402968
- Where
- 2 sites in United States, France
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Depressive Disorder, Depression
A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial
To compare the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy to an assigned open label antidepressant therapy (ADT) in the proposed subject population with MDD.
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- NCT01727726
- Testing
- Brexpiprazole, Seroquel XR
- Where
- 76 sites in United States, Canada and 5 more
- Volunteers
- 2,182 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary IgA Nephropathy
The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease
The objective of the study is to evaluate efficacy and safety of two different doses of NEFECON in the treatment of patients with primary IgA nephropathy (IgAN) at risk of developing end-stage renal disease, under rigorous blood…
- Trial name
- NEFIGAN (NCT01738035)
- Testing
- NEFECON
- Where
- 58 sites in Belgium, Czechia and 8 more
- Volunteers
- 150 people
- Sponsor
- Calliditas Therapeutics AB
Hypertension
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen
A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with…
- Trial name
- NCT05769608
- Testing
- lorundrostat Dose 1, lorundrostat Dose 2
- Where
- 104 sites in United States
- Volunteers
- 285 people
- Sponsor
- Mineralys Therapeutics Inc.
Hypovolemia
Study on the Efficacy and Safety of Gelaspan
It is the objective of the study to investigate the efficacy and safety of two different volume replacement regimens with gelatine solutions.
- Trial name
- NCT02808325
- Testing
- Gelaspan 4%, Gelofusine 4%
- Where
- 3 sites in Russia
- Volunteers
- 72 people
- Sponsor
- B. Braun Medical LLC
Arthritis, Psoriatic
Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy
The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to Nonsteroidal anti-inflammatory drugs (NSAIDs) and…
- Trial name
- NCT01490450
- Testing
- BMS-945429
- Where
- 49 sites in United States, Argentina and 11 more
- Volunteers
- 165 people
- Sponsor
- CSL Behring
Progressive Supranuclear Palsy
Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy
Study hypothesis: A 6-week p.o treatment with 5 mg/Kg Coenzyme Q10 is safe and tolerable,increases the brain's metabolism and ameliorates clinical symptoms in patients with PSP.
- Trial name
- NCT00328874
- Testing
- Coenzyme Q10
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- German Parkinson Study Group (GPS)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.